<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A single masked trial of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> 5 mg/kg/day versus monthly 1 g intravenous boluses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> was conducted among 23 patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome and active, potentially reversible <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The trial was unmasked after a mean of 12 (SD 2) months for the <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> group (n = 12) and a mean of 10 (SD 3) months for the <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> group (n = 11) </plain></SENT>
<SENT sid="2" pm="."><plain>During the initial 6 months the visual acuity significantly improved (p &lt; 0.001) in the <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> group whereas this was not observed in the <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> group </plain></SENT>
<SENT sid="3" pm="."><plain>The subsequent follow-up of patients up to 24 months suggested that the initial improvement in visual acuity with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> was not sustained </plain></SENT>
<SENT sid="4" pm="."><plain>More extensive and especially long-term studies of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> in the <z:hpo ids='HP_0000554'>uveitis</z:hpo> of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome are warranted </plain></SENT>
</text></document>